Prostaglandins but not leukotrienes alter extracellular matrix protein deposition and cytokine release in primary human airway smooth muscle cells and fibroblasts. Am J Physiol Lung Cell Mol Physiol 303: L239-L250, 2012. First published May 25, 2012 doi:10.1152/ajplung.00097.2012.-Eicosanoids are lipid-signaling mediators released by many cells in response to various stimuli. Increasing evidence suggests that eicosanoids such as leukotrienes and prostaglandins (PGs) may directly mediate remodeling. In this study, we assessed whether these substances could alter extracellular matrix (ECM) proteins and the inflammatory profiles of primary human airway smooth muscle cells (ASM) and fibroblasts. PGE 2 decreased both fibronectin and tenascin C in fibroblasts but only fibronectin in ASM. PGD 2 decreased both fibronectin and tenascin C in both ASM and fibroblasts, whereas PGF 2␣ had no effect on ECM deposition. The selective PGI2 analog, MRE-269, decreased fibronectin but not tenascin C in both cell types. All the PGs increased IL-6 and IL-8 release in a dose-dependent manner in ASM and fibroblasts. Changes in ECM deposition and cytokine release induced by prostaglandins in both ASM and fibroblasts were independent of an effect on cell number. Neither the acute nor repeated stimulation with leukotrienes had an effect on the deposition of ECM proteins or cytokine release from ASM or fibroblasts. We concluded that, collectively, these results provide evidence that PGs may contribute to ECM remodeling to a greater extent than leukotrienes in airway cells.
eicosanoids; tenascin C; fibronectin; airway remodeling ASTHMA IS A CHRONIC INFLAMMATORY disease associated with the larger airways, whereas chronic obstructive pulmonary disease (COPD) is more commonly associated with the smaller airways.
In both lung diseases, structural changes to the airways, also known as airway remodeling, occur. Although the mechanisms that cause airway remodeling are still undefined and may be distinct between the diseases, airway remodeling is strongly associated with dysfunctional lung physiology.
In COPD, a characteristic feature of airway remodeling is the destruction of the alveolar walls, which results in reduced gas exchange and translates to the symptoms of difficulty in breathing, whereas, in asthma, difficulty in breathing may stem from the features of increased thickness of the epithelial layers and smooth muscle bulk in the airway wall, which contribute to increased airway contraction and obstruction. However, one structural characteristic present in both diseases is the increased connective tissue within the airway wall.
Connective tissue is composed of scaffolding proteins termed the extracellular matrix (ECM), and it is not only the absolute amount of ECM that varies in disease but the individual constituents that are also differentially regulated. ECM proteins are produced by all the structural cells of the airways including epithelial, airway smooth muscle (ASM), and fibroblasts. They influence cellular proliferation, migration, the deposition of other ECM proteins, and cytokine and growth factor secretion and play an essential role in maintaining a healthy cellular system (10, 23, 30, 57) .
Tenascin C (TnC) and fibronectin (Fn) are highly conserved, high-molecular-weight glycoproteins with quite different actions. They are increased in respiratory diseases such as asthma and COPD, and their presence is associated with structural remodeling and/or inflammation in the airways (5, 38) . However, the reasons why they accumulate remain unclear.
TnC is tightly regulated during development, and its levels increase during embryogenesis but otherwise remain low and regulated during postnatal life, appearing in areas such as tendons and ligaments during infection, inflammation, tissue remodeling, and cancer. TnC knockout mice do survive; however, they have deficiencies in other ECM proteins as well as mental, vision, and healing abnormalities (42) . TnC has some proadhesive properties but is more renowned for its antiadhesive properties such as reduction in the spreading of cells and enhancing cancer cell migration, invasiveness, and proliferation (13, 22, 50, 56, 68) .
Fn exists as either a soluble or insoluble form and is often found surrounding cells and/or in the basement membrane. Fn knockout mice die within the first few days during embryogenesis, which highlights its importance in cellular development (19, 45) . Fn has vital roles in cell adherence, spreading, and migration (45) .
Eicosanoids are lipid mediators derived from arachidonic acid, and they include the prostaglandins and leukotrienes, which are produced by the cyclooxygenase and the 5-lipoxygenase pathways, respectively. Emerging evidence suggests that the prostaglandins and leukotrienes may be involved in airway remodeling, and one possible way is by altering the deposition of ECM proteins (21) .
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For this reason, in this study, we investigated the ability of prostaglandins and leukotrienes to affect ECM production, in particular TnC and Fn, as well as release of the cytokines interleukin (IL)-6 and IL-8, markers for inflammation from airway mesenchymal cells.
MATERIALS AND METHODS
Drugs. LTB4, C4, D4, and E4 were dissolved in ethanol (EtOH), whereas PGD2, E2, and F2␣ and the PGI2 analog MRE-269 (all purchased from Cayman Chemicals, Ann Arbor, MI) were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Saint Louis, MO) purged with nitrogen gas to prevent lipid oxidation and stored at Ϫ80°C before use. The exchange protein directly activated by cyclic adenosine monophosphate (cAMP) (EPAC) protein inhibitor brefel- ASM, airway smooth muscle; HBEC, human bronchial epithelial cells; BFA. brefeldin A; ITS, insulin transferrin selenium (serum free) medium; B4/C4/D4/E4, leukotriene (LT) B4/C4/D4/E4 isotypes; E2/D2/F2␣, prostaglandin (PG) E2/D2/F2␣ isotypes; MRE-269, PGI2 analog ; ϩTϭ in the presence of TGF-␤. NSCCA, non-small cell carcinoma; Ca, Cancer; LCCA, large cell carcinoma; SCCA, small cell carcinoma; Adeno Ca, adenocarcinoma; COPD, chronic obstructive pulmonary disease; T, transplantation; R, resection; B, biopsy.
din A (Sigma-Aldrich) was also dissolved in DMSO and stored at Ϫ80°C before to use.
Cell culture: human bronchial epithelial cells, ASM, and fibroblasts. Primary human bronchial epithelial cells (HBEC), ASM, and parenchymal fibroblasts were obtained from lung specimens with approval from the human ethics committees of The University of Sydney and the Sydney South West Area Health Service. Cells were isolated from macroscopically normal airway and parenchyma of 48 different patients undergoing lung resection or transplantation for mostly either carcinoma or emphysema. All patients provided written informed consent for the collection, and study of their tissue and all patient details are shown in Table 1 . Because there were no statistically different responses to eicosanoids in cells from patients with different disease diagnoses, results were pooled and analyzed together in this study.
HBEC and ASM were obtained from human bronchial airways and fibroblasts from lung parenchyma by methods previously described (8, 35, 55) . Briefly, segments of bronchus were dissected free from the surrounding parenchyma, cut open, and washed in Hanks' balanced salt solution (HBSS) (Invitrogen, Carlsbad, CA). The epithelium was removed and collected into 75-cm 2 flasks with bronchial epithelial growth medium (BEGM) (Clonetics, San Diego, CA). In doing so, this exposes the underlying bands of smooth muscle, which were then gently separated from the underlying connective tissue in small bundles (smooth muscle cell explants). The explants were transferred into 25-cm 2 flasks and covered with a minimal amount of DMEM containing 1% antibiotics: 20 U/l of penicillin, 20 g/ml of streptomycin, 2.5 g/ml of amphotericin B, and 10% FBS (all purchased from Invitrogen). Fibroblasts were isolated from resected lung tissue by seeding 1-2-mm 3 pieces of parenchymal tissue into DMEM supplemented with 10% FBS and 1% antibiotics in 75-mm 2 flasks. All cell types were incubated at 37°C in a humidified atmosphere of 5% CO2-95% air.
The medium was replenished every 5 days for the first 10 -20 days, and, within this time, cell growth occurred. The cells were passaged (split 1:3) with a solution of trypsin (0.05% wt/vol in HBSS) containing 1 mM EDTA. The cells were maintained in DMEM supplemented with 1% antibiotics 10% FBS, whereas HBEC were maintained in BEGM. All cells were tested for mycoplasma contamination, and only mycoplasma-free cells were selected and passaged once they reached confluence. ASM and fibroblasts at passages 3-7 and HBEC at passages 2-3 were used for experimentation.
Stimulation. HBEC, ASM, and fibroblasts were seeded into 96-well plates at a concentration of 1 ϫ 10 4 cells per cm 2 in 10% FBS DMEM and grown to subconfluence (3 days) and then quiesced in 0.1% FBS DMEM for 1 day. Because lipid mediators eicosanoids bind to serum albumin with high affinity and this reduces their activity, the cells were therefore stimulated once with no stimulus (control), transforming growth factor ␤ (TGF-␤) (1 ng/ml) (R&D Systems, Minneapolis, MN), various leukotrienes (10 Ϫ10 -10 Ϫ6 M) and prostaglandins (10 Ϫ9 -10 Ϫ5 M), corresponding vehicle controls either EtOH or DMSO for 1 and 3 days in DMEM supplemented with or without 0.1% FBS or 0.1% insulin-transferrin-selenium (ITS) (Invitrogen, Grand Island, NY). In initial experiments, we established that TGF-␤-induced Fn, TnC, IL-6, and IL-8 were maximal 72 h poststimulation compared with earlier time points (data not shown). We therefore chose 72 h as the time point for all future experiments. To mimic the possibility of repeated exposure to leukotrienes, which may lead to airway remodeling in asthma in our in vitro model, the cells were stimulated once a day for 5 days with LTD4, the most potent of all leukotrienes (7), in the presence of 0.1% FBS with the above conditions.
After stimulation, the culture medium was collected and the cells were then lysed in 0.016 M sterile hypotonic ammonium hydroxide (Sigma-Aldrich), and deposited ECM proteins were washed in PBS. The plates were then loaded with fresh PBS and stored at Ϫ20°C for ECM ELISA analysis, whereas supernatants were stored at Ϫ80°C (29) . In experiments using brefeldin A, cells were pretreated for 1 h as well as during PGE2 stimulation with brefeldin A at 10 Ϫ6 M.
Cell counting. Viable cells were counted manually using a hemocytometer. Following trypsinization, cells were mixed with trypan blue (0.02% wt/vol) (Sigma-Aldrich) in a 1:1 ratio and placed into a hemocytometer. Viable cells were unstained and counted, and the total number of cells was calculated.
ECM ELISA. ECM proteins were measured by ELISA as described (29) for Fn (mouse anti-human monoclonal fibronectin COOH-terminal, 2 g/ml; Invitrogen), and TnC (mouse anti-tenascin, clone BC-24 ascites fluid 1:8,000 dilution; Sigma-Aldrich). Other reagents used included mouse-purified IgG 1 isotype control (2 g/ml, clone MOPC-31C; BD Bioscience, San Jose, CA), anti-mouse Ig horseradish peroxidase (HRP) (polyclonal rabbit anti-mouse immunoglobin/HRP, Dako, Campbellfield, Victoria, Australia). Plates were developed Fig. 1 . Superimposed concentration-response curves relating the effects of TGF-␤ on fibronectin (Fn), tenascin C (TnC), IL-6, and IL-8 in airway smooth muscle (ASM) (A) and fibroblasts (B). ASM (A, n ϭ 4) and fibroblasts (B, n ϭ 4) were stimulated with the control (0 ng/ml TGF-␤) or TGF-␤ from 0.1-30 ng/ml for 72 h. Changes in Fn (solid black lines) and TnC (solid gray lines) were measured using extracellular matrix (ECM) ELISAs, whereas changes in IL-6 (dashed gray lines) and IL-8 (dashed black lines) were measured using soluble ELISAs. Data depict the superimposed percentage of protein responses to different concentrations of TGF-␤ compared with the 1 ng/ml TGF-␤ control as means Ϯ SE. Statistical differences were detected using 1-way ANOVA by comparing individual TGF-␤ concentrations with the control; *P Ͻ 0.05, and "-" represents no significance P Ͼ 0.05. using 2,2=-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (SigmaAldrich) and read using a spectroplate reader at a wavelength of 405 nm. Fn but not TnC was detectable in culture medium regardless of treatment conditions, and for this reason Fn ELISA results were corrected against wells with only culture medium in the absence of cells. Results were averaged from triplicate wells and expressed as raw arbitrary optical density values to allow for statistical comparison of differences between stimulus and respective vehicle controls. Because the units of measure of this ELISA are arbitrary, internal experimental positive and negative controls were always in place. Wells treated with TGF-␤ (1 ng/ml) induced maximum Fn and TnC deposition (Fig. 1) and served as the positive control, whereas wells with no cells and only culture medium, which would express the least output (after correction in the case of Fn), served as the negative control.
Cytokine ELISA. ELISA kits for IL-6 and IL-8 were purchased from R&D Systems and BD Biosciences, respectively. ELISAs were carried out according to the manufacturers' instructions. The detection limits of these assays were 7.8125 pg/ml (IL-6) and 15.625 pg/ml (IL-8) .
Statistical analysis. All data were analyzed for normal distribution, and the values are presented as means Ϯ SE. When results were nonparametrically distributed, the dataset was log transformed before statistical analysis using GraphPad Prism Version 5 software (La Jolla, CA). ELISA results were analyzed either by one-way ANOVA with Bonferroni posttest corrections to compare with appropriate vehicle controls or by a paired Student's t-test where appropriate. Statistical significance was shown when P Յ 0.05. In some results, after statistical analysis, raw values from each ELISA were expressed as a percentage of vehicle control and presented as superimposed concentration-response curves relating the effects of the various prostaglandins on Fn, TnC, IL-6, and IL-8 in ASM and fibroblasts.
RESULTS
TGF-␤ induces maximal ECM deposition and cytokine release at 1 ng/ml. Statistical significance was detected in TGF-␤-induced Fn and TnC deposition and IL-6 and IL-8 release from as low as 0.3 ng/ml compared with the control, which is free of TGF-␤ (0 ng/ml) from ASM and fibroblasts (both n ϭ 4, P Ͻ 0.05, Fig. 1 ). In both cell types, TGF-␤ from 0.1 to 30 ng/ml caused a dose-related increase in the TGF-␤-induced proteins with maximal induction at 1 ng/ml followed by a plateau (both n ϭ 4, Fig. 1 ). For this reason, the submaximal dose of TGF-␤ at 0.3 ng/ml was selected for experiments carried out in the presence of PGE 2 and PGD 2 to observe whether they could alter TGF-␤-induced Fn, TnC, IL-6, and IL-8 in ASM and fibroblasts. TGF-␤ at 1 ng/ml was used as a positive experimental control for all subsequent analyses for the positive induction of Fn and TnC (P Ͻ 0.05).
Prostaglandins alter basal ECM deposition and cytokine release in ASM. PGE 2 (n ϭ 8) and MRE-269 (n ϭ 4) from 10 Ϫ9 to 10 Ϫ5 M decreased Fn deposition in ASM, whereas PGD 2 (n ϭ 18) only decreased Fn at 10 Ϫ5 M (P Ͻ 0.05, Fig. 2 ). Additionally, PGF 2␣ (n ϭ 8) had no effect on Fn deposition, and none of the prostaglandins had an effect on TnC deposition in ASM (PGE 2 M-10 -5 M) for 72 h. Changes in Fn (A) and TnC (B) were measured using ECM ELISAs, while changes in IL-6 (C) and IL-8 (D) were measured using soluble ELISAs. Data depict the superimposed percentage of responses of prostaglandin to its vehicle control as means Ϯ SE. Statistical differences were detected using 1-way ANOVA by comparing the original raw results for each drug concentration with its corresponding vehicle; *P Ͻ 0.05 and "-" represents no significance P Ͼ 0.05.
2). Increasing concentrations of PGE 2 from 10
Ϫ8 M, PGD 2 from 10 Ϫ6 M, and PGF 2␣ from 10 Ϫ7 M caused an increase in IL-6 release in ASM, whereas prostaglandin concentrations above 10 Ϫ6 M all caused increased release of IL-8 from ASM (n ϭ 8, 18, and 4, respectively, P Ͻ 0.05, Fig. 2 ). MRE-269 (n ϭ 4) from 10 Ϫ9 -10 Ϫ5 M increased IL-6 uniformly (P Ͻ 0.05) but had no effect on IL-8 release from ASM (Fig. 2) .
Prostaglandins alter basal ECM deposition and cytokine release in fibroblasts. PGE 2 (n ϭ 8) and MRE-269 (n ϭ 4) from 10 Ϫ9 to 10 Ϫ5 M decreased Fn and TnC deposition in fibroblasts, whereas PGD 2 (n ϭ 11) decreased both proteins at 10 Ϫ5 M (P Ͻ 0.05, Fig. 3 ). PGF 2␣ had no effect on either Fn or TnC deposition in fibroblasts (n ϭ 4, Fig. 3 ).
Increasing concentrations of PGE 2 from 10 Ϫ8 M, PGD 2 from 10 Ϫ6 M, and PGF 2␣ from 10 Ϫ6 M caused an increase in IL-6 and IL-8 release in fibroblasts (n ϭ 8, 11, and 4, respectively, P Ͻ 0.05, Fig. 3 ). MRE-269 had no effect on IL-6 release but from 10 Ϫ6 M decreased IL-8 release (n ϭ 4, P Ͻ 0.05, Fig. 3 ).
Brefeldin A prevents PGE 2 -induced reduction of Fn deposition in ASM and fibroblasts.
We demonstrated that PGE 2 reduced Fn deposition in ASM and fibroblasts. The EPAC inhibitor brefeldin A (10 Ϫ6 M) alone did not alter the constitutive levels of Fn deposition in ASM (n ϭ 6) and fibroblasts (n ϭ 5) (data not shown). In the presence of brefeldin A (10 Ϫ6 M), PGE 2 from 10 Ϫ7 to 10 Ϫ5 M-induced reduction of Fn deposition in ASM (n ϭ 6) and fibroblasts (n ϭ 5) was prevented (P Ͻ 0.05, Fig. 4) .
Prostaglandin E 2 and D 2 decreased TGF-␤-induced Fn deposition and increased cytokine release in ASM.
TGF-␤ at 1 ng/ml induced the maximal response for ECM deposition and cytokine release (Fig. 1) , and therefore a submaximal concentration (0.3 ng/ml) was used in this series of experiments. In ASM, PGE 2 from 10 Ϫ8 to 10 Ϫ5 M and PGD 2 at 10 Ϫ5 M decreased TGF-␤-induced Fn deposition (n ϭ 4, P Ͻ 0.05, Fig. 5 ), but neither prostaglandins at any concentration altered TGF-␤-induced TnC. PGE 2 from 10 Ϫ6 M and PGD 2 at 10 Ϫ5 M increased TGF-␤-induced IL-6 release, whereas PGE 2 and PGD 2 both at 10 Ϫ5 M increased TGF-␤-induced IL-8 in ASM (n ϭ 4, P Ͻ 0.05, Fig. 5) .
PGE 2 and PGD 2 decreased TGF-␤-induced Fn deposition and increased cytokine release in fibroblasts. In fibroblasts, PGE 2 decreased TGF-␤-induced Fn deposition from 10
Ϫ8 M and TnC deposition from 10 Ϫ7 M (n ϭ 4, P Ͻ 0.05, Fig. 6 ), whereas PGD 2 decreased both TGF-␤-induced Fn and TnC deposition only at 10 Ϫ5 M (n ϭ 4, P Ͻ 0.05, Fig. 6 ). PGE 2 did not alter TGF-␤-induced IL-6 but did increase TGF-␤-induced IL-8, whereas PGD 2 increased both cytokines at 10 Ϫ5 M (n ϭ 4, P Ͻ 0.05, Fig. 6 ).
Leukotrienes do not alter ECM deposition or cytokine release. Acute stimulation with LTB 4 , C 4 , D 4 , and E 4 did not cause any changes in the levels of Fn or TnC or cytokines IL-6 and IL-8 (n ϭ 3, 3, 8, and 8, respectively, data not shown). This was also the case with LTD 4 and LTE 4 at 10 Ϫ7 -10 Ϫ6 M in ITSsupplemented medium, i.e., the absence of serum (both n ϭ 4 data Repeated stimulation with LTD 4 does not alter the ECM. ASM and fibroblasts repeatedly stimulated, once a day for 5 days, using LTD 4 at 10 Ϫ7 M compared with its vehicle control did not cause any changes in either ECM protein in ASM and fibroblasts (both n ϭ 4, Fig. 7) .
Prostaglandins do not alter proliferation, whereas LTD 4 synergistically induces proliferation in ASM in the presence of EGF. As a positive control, ASM (n ϭ 6) and fibroblasts (n ϭ 3) in the presence of 10% FBS had higher proliferation than cells in the presence of quiescent medium of 0.1% FBS (P Ͻ 0.05, data not shown). Under the experimental conditions used for the analysis of ECM proteins, PGE 2 , PGD 2 , PGF 2␣ , and MRE-269 at 10 Ϫ7 M and 10 Ϫ5 M did not alter the proliferation of ASM (n ϭ 4, 4, 4, and 6, respectively) or fibroblasts (n ϭ 3, 3, 3, and 3, respectively) in 0.1% FBS (data not shown). This suggests that, within these experimental conditions, changes in ECM deposition and cytokine release caused by prostaglandins were independent of cell number.
ASM cells stimulated with 10% FBS or EGF (1 ng/ml) induced ASM proliferation compared with control (P Ͻ 0.05, n ϭ 8, Fig. 8 ). Stimulation with LTD 4 (10 Ϫ6 M) alone did not alter ASM proliferation, but, in the presence of EGF (1 ng/ml), there was a synergistic increase in ASM proliferation compared with that induced by EGF alone (P Ͻ 0.05, n ϭ 8, Fig.  8 ), confirming the findings by Panetierri et al. (49) that, although leukotrienes had no effect on Fn or TnC deposition, the cells did respond to these stimuli.
LTD 4 induces TnC but not Fn in primary HBECs. To confirm the activity of LTD 4 , primary HBECs were treated with LTD 4 at 10
Ϫ6
M for 72 h. Compared with its vehicle control, LTD 4 increased TnC (P Ͻ 0.05) but not Fn deposition (n ϭ 7, Fig. 9 ) in HBEC.
DISCUSSION
This study investigated in vitro whether prostaglandins and leukotrienes could alter the deposition of ECM proteins or release of cytokines from ASM and fibroblasts either alone or in the presence of TGF-␤. The prostaglandins caused differential changes in the basal deposition of ECM proteins. PGE 2 , PGD 2 , and MRE-269 but not PGF 2␣ reduced basal and TGF-␤-induced ECM deposition, and, apart from the PGI 2 analog MRE-269, all the prostaglandins induced cytokine release, which was not due to changes in proliferation. On the other hand, stimulation with leukotrienes either acutely or repeatedly did not alter ECM deposition or cytokine release from either ASM or fibroblasts, even though the most potent of all leukotrienes, LTD 4 , was functionally active and induced synergistic ASM proliferation in the presence of EGF and caused increased deposition of TnC in HBECs. This result was not influenced by the presence of serum and/or the profibrotic factor TGF-␤.
We confirmed our earlier findings that PGE 2 decreased TGF-␤-induced Fn in ASM (9) and in addition also found reduced basal Fn. The same response occurred in fibroblasts. In contrast, PGE 2 decreased TnC only in fibroblasts.
The mechanism by which PGE 2 inhibits Fn may be via activation of EPAC. EPAC proteins have recently been found in airway cells including ASM, epithelial cells, and fibroblasts (24, 25, 54) . Activation of EPAC results in increased matrix metalloproteinase 9 (MMP-9) in both epithelial and ASM cells (54) , and, because MMP 9 degrades Fn (43) but not TnC (59) , this may explain why only Fn deposition is reduced. Brefeldin A has a broad effect on cellular activity such as the ability to inhibit intracellular protein exchange as well as vesicular trafficking (66) . Even though the mechanism remains unclear, it has also been shown to be able to inhibit EPAC proteins (69). When we inhibited EPAC proteins using brefeldin A, we were able to restore PGE 2 induced reduction in Fn deposition in both ASM and fibroblasts, thus supporting this hypothesis. To fully test this hypothesis, there is a need for more specific and defined EPAC antagonists, which unfortunately are currently unavailable (20) . TnC is a highly investigated ECM protein in cancer, where increased expression of TnC but not Fn occurs. This ratio imbalance between the levels of Fn and TnC is present at the border of tumors, where cellular invasion, migration, and proliferation occur (6) . ECM proteins including TnC and Fn are present in increased amounts in the airway walls of patients with asthma or COPD (5, 38) and the levels of detectable PGE 2 in sputum are higher in asthmatic patients than nonasthmatic patients (1, 41, 53) . However, it is not M) (black) for 72 h. Changes in Fn were measured using ECM ELISAs, and results are expressed as raw optical density (OD) arbitrary values. Data represent means Ϯ SE. Statistical differences were detected using 1-way ANOVA by comparing the results of vehicle with brefeldin A at each concentration of PGE2, *P Ͻ 0.05. Changes in Fn (A) and TnC (B) were measured using ECM ELISAs, whereas changes in IL-6 (C), and IL-8 (D) were measured using soluble ELISAs. Data depict the superimposed percentage of responses of PGE2 and PGD2 to its vehicle control in the presence of TGF-␤ as means Ϯ SE. Statistical differences were detected using 1-way ANOVA by comparing the original raw results for each drug concentration with its corresponding vehicle in the presence of TGF-␤; *P Ͻ 0.05 and "-" represents no significance P Ͼ 0.05. M) in the presence of TGF-␤ (0.3 ng/ml) for 72 h. Changes in Fn (A) and TnC (B) were measured using ECM ELISAs, whereas changes in IL-6 (C) and IL-8 (D) were measured using soluble ELISAs. Data depict the superimposed percentage of responses of PGE2 and PGD2 to its vehicle control in the presence of TGF-␤ as means Ϯ SE. Statistical differences were detected using 1-way ANOVA by comparing the original raw results for each drug concentration with its corresponding vehicle in the presence of TGF-␤; *P Ͻ 0.05 and "-" represents no significance P Ͼ 0.05.
known whether the levels of TnC are greater than Fn in the airways of other fibrotic diseases. We postulate that the lack of inhibition by PGE 2 of TnC results in this imbalance between the levels of TnC and Fn in the airways and may influence ASM hypertrophy and hyperplasia via similar mechanisms. There is little information on the role of PGD 2 or PGF 2␣ on airway remodeling. PGD 2 acts via DP1 and 2 receptors, both of which are present on ASM and fibroblasts (14, 32) , whereas PGF 2␣ acts on the FP receptor, which has been detected in lung fibroblasts and has been shown to facilitate bleomycin-induced pulmonary fibrosis (47) . Because PGF 2␣ did not alter the deposition of ECM proteins, it is possible that it may not be involved in the regulation of these ECM proteins. However, we did find that PGD 2 inhibited basal and TGF-␤-induced Fn in both ASM and fibroblasts but TnC only in fibroblasts. It is likely that prostaglandins of one subtype have the ability to activate receptors of another subtype. For example, Kang et al. (31, 48) were able to show that PGF 2␣ can crossactivate thromboxane receptors and cause bronchoconstriction in mouse lungs, and similarly it is argued that high levels of PGE 2 and PGD 2 can activate FP receptors and trigger fibrotic changes downstream. Therefore, because the concentrations at which the effects mediated by PGD 2 are observed are much higher than other prostaglandins, it is possible that crossactivation with other prostaglandin receptors, such as the EP receptors, occurs and hence explain this effect. This hypothesis should be investigated further in future when more selective agonists become available. PGI 2 induces arterial smooth muscle relaxation and is used clinically to treat severe hypertension (18) . MRE-269 is a stable analog of PGI 2 and specifically binds to the IP receptor (15, 37) . MRE-269 decreased FN deposition in both ASM and fibroblasts and only TnC in fibroblasts. There is very little research into the role of PGI 2 in airway remodeling; however, it has been shown recently that, during the process of wound healing in mice and human fibroblasts, PGE 2 levels increase during the early stage to induce inflammatory cell infiltration, whereas PGI 2 levels increase when the process is nearly complete. It is speculated that PGI 2 may be the mediator to switch off remodeling seen in fibrotic diseases (62) . Whether this is true in airway diseases requires further investigation.
There are many studies that have examined the effects of prostaglandins on IL-6 and IL-8 release from nonrespiratory cell types in the body. For example, PGE 2 can induce IL-6 from astrocytes, osteoblasts, and IL-8 from human colon epithelial cells, PGD 2 can induce IL-6 release from osteoblasts, and PGF 2␣ can induce IL-8 release from dental pulp cells (11, 17, 33, 64, 67) . Very few studies have examined these effects in respiratory cell types. Of the few studies that exist, Tavakoli et al. (63) showed that PGE 2 induced IL-6, Chiba et al. (12) showed that PGD 2 induced IL-8 in human bronchial epithelial cells, and Ammit et al. (3) showed that PGE 2 increased IL-6 in ASM. To our knowledge, our investigation supports what is already known about PGE 2 in these structural cells but is the first to examine and show that PGD 2 and PGF 2␣ increases IL-6 and IL-8 release in primary human ASM and fibroblasts.
The classical mechanism by which most eicosanoid ligands that activate G(s)-G protein-coupled receptors (GPCR), such as PGE 2 and PGD 2 , increase cytokine release is via the cAMP/ protein kinase A pathway, leading to activation of the cAMP response element-binding protein and upregulation of the IL-6/8 genes (4, 52) . PGF 2␣ , on the other hand, activates the G(q)-GPCR and upregulates cytokine gene transcription due to the activation of the extracellular-signal-regulated kinase, which may affect the cAMP pathway (11) .
MRE-269, however, did not show similar behavior, as it increased IL-6 but not IL-8 in ASM and vice versa in fibroblasts. The IP receptor is a G(s) protein receptor, and its activation may increase cytokine release via the same pathway as the other prostaglandins. However, it may also activate other pathways, which could inhibit another cytokine. PGE 2 decreases FBS-induced proliferation of ASM and fibroblasts (9, 28) . Interestingly, we found that the prostaglandins did not have any pro-or antiproliferative effects on quiesced mesenchymal cells, suggesting that the effects on ECM proteins and cytokine were independent of an effect on cell number.
Despite recent evidence suggesting that leukotrienes play a role in airway remodeling, we found that leukotrienes did not alter Fn or TnC deposition or IL-6 and IL-8 release in ASM or fibroblasts. This lack of effect occurred regardless of whether the cells were stimulated with leukotrienes acutely or repeatedly. The presence of another profibrotic factor TGF-␤ did not influence ECM deposition, which was also observed by Panettieri et al. (49) . This is unlikely to be the result of leukotriene inactivation by albumin (70) , as experiments repeated in the absence of serum yielded the same results. To confirm that we were in fact using active leukotrienes, we repeated the findings first described by Panetierri et al. (49) that LTD 4 in the presence of EGF caused synergistic induction of ASM proliferation. This also confirms the presence of functional leukotriene receptors on ASM. We further demonstrated its activity by showing that LTD 4 can induce TnC deposition in primary HBEC. Our results support the original in vitro study by Altraja et al. (2) that showed that leukotrienes increased TnC in a transformed epithelial cell line BEAS-2B, and in addition we have extended this finding using primary HBECs.
Although leukotrienes may simply just lack a direct effect on ASM and fibroblasts, one possibility for the lack of effect of leukotrienes on ASM and fibroblasts may be due to limitations of the in vitro setting. Our investigation was set out to determine the effects of leukotrienes in the in vitro monocellular setting using primary human lung cells, which, although a better representation of human cellular behavior than trans- Statistical differences between vehicle and LTD4 responses were detected using a paired t-test, *P Ͻ 0.05. Fig. 8 . LTD4 in the presence of epidermal growth factor (EGF) (1 ng/ml) synergistically increased ASM proliferation. ASM (n ϭ 8) in the presence of vehicle were stimulated with 10% FBS, LTD4 (10 -6 M), EGF (1 ng/ml), or both LTD4 and EGF (10 -6 M and 1 ng/ml, respectively) for 24 h and viable cells were counted using trypan blue exclusion, and results are expressed as cell number per well. Data represent means Ϯ SE. Statistical differences were detected using 1-way ANOVA by comparing each stimulation with its respective controls: 0.001% insulin-transferrin-selenium or EGF (1 ng/ml), *P Ͻ 0.05. formed cell lines, may still be quite difficult to mimic exactly in in vivo situations. It is possible that the effects of leukotrienes may require an environment with multiple cell types and interaction of both structural and inflammatory cells. In this case, a more sophisticated model system such as the use of bronchial tissue explants could better mimic in vivo conditions and should be investigated in the future.
It is now well accepted that the ECM plays an essential role in maintaining cellular development and inflammation, and an abnormal ECM profile is a common characteristic of fibrotic airway disorders. Our study shows that, compared with the leukotrienes, the prostaglandins have a greater ability to modulate ECM deposition and cytokine release, at least in ASM and fibroblasts. Prostaglandins are therefore more likely to be implicated in airway remodeling via the alteration of the ECM by ASM and fibroblasts. 
